The Evidence Based Rheumatology Podcast

Really interesting study this week comparing the IL17 inhibitor ixekizumab WITH the GLP1 inhibitor tirzepatide to ixekizumab alone. Raises some interesting questions about what worked here and whether or not it matters how it worked. 

 

Paper: https://acrjournals.onlinelibrary.wiley.com/doi/10.1002/art.70134

Newsletter: http://autoimmunedevreport.com/

Great trial this week looking at brepocitinib in dermatomyositis. Looks like a winner, expect it will be approved. Where it fits in our approach to IIM is an open question, but nice to have another option. 

Study: https://www.nejm.org/doi/10.1056/NEJMoa2503531

JC Companion: https://autoimmunedevreport.substack.com/

Good RCT this week, investigating the CD20 B cell inhibitor obinutuzumab for SLE. Sign up for my newsletter if you would like to have a read-along companion piece! 

 

Paper: https://www.nejm.org/doi/full/10.1056/NEJMoa2516150

Landing Page: https://ebrheum.com/

Substack: https://autoimmunedevreport.substack.com/

Quick podcast this week about a nifty head to head study that I had previously missed. Worth reading if - like me - you're still trying to figure out how the heck to manage osteoporosis. 

Paper: https://pubmed.ncbi.nlm.nih.gov/28755782/

Today I cover the recent publication of the RESET-RA study, which evaluated vagal nerve stimulation to treat rheumatoid arthritis. Have a listen in full, but let me be clear upfront: I do not think this works and will not be referring any patients to receive it. This will forever be my pivotal example of the effect of unblinding, but would love to hear if you think different! 

 

Paper: https://www.nature.com/articles/s41591-025-04114-7

Supplement (see S4): https://www.nature.com/articles/s41591-025-04114-7#Sec27